Skip to main content

Advertisement

Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma

Fig. 5

PB2 enhanced the chemosensitivity of sorafenib (SORA) in HCC cells in vivo and in vitro. a The combined effect of PB2 and SORA on the metabolic enzymes of HCC cells, by western blotting analysis. b The combined effect of PB2 and SORA on the glucose uptake and supernatant lactate levels in HCC cells. c, d PB2 and SORA co-treatment suppressed the growth and volume of mouse xenograft tumors. e The hematoxylin and eosin TUNEL staining of tumor sections. PB2 and SORA co-treatment increased the necrosis and apoptosis in tumor tissues. *P < 0.05 vs. the normal control group; #P < 0.05 vs. the SORA group (5B&5D: one-way ANOVA)

Back to article page